Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | APAF1 | O14727 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MPO | P05164 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | FNTA | P49354 | 1/20 | 0.51 |
| ▸ | FNTB | P49356 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL162554 | 1.00 | MAPT (0.54) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL343309 | 1.00 | MAPT (0.54) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL30135703 | 1.00 | MAPT (0.54) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL29434606 | 1.00 | MAPT (0.54) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL29355137 | 1.00 | MAPT (0.54) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL29588649 | 1.00 | MAPT (0.54) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8995746 | 0.99 | MAPT (0.52) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6112940 | 0.99 | MAPT (0.52) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| Metyrosine SCHEMBL2722717 | 0.90 | BLM (0.62) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL10077124 | 0.88 | MEN1 (0.52) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1939 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230220387-A1 | D-SERINE TRANSPORT MODIFIER AND SCREENING METHOD THEREOF, AND SCREENING METHOD OF D-SERINE TRANSPORTER PROTEIN | KAGAMI INC. (JP) | 2023-07-13 | — | — | US | claimed |
| US-20090215895-A1 | Therapeutic and carrier molecules | PEPLIN BIOLIPIDS PTY LTD (AU) | 2009-08-27 | — | — | US | claimed |
| US-7256172-B1 | Method of treatment and agents useful for same | THE UNIVERSITY OF MELBOURNE (AU) | 2007-08-14 | — | — | US | claimed |
| US-7070969-B1 | Plasmin inhibitors from the australian brown snake Pseudonaja textilis textilis | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-07-04 | — | — | US | claimed |
| EP-0405537-B1 | N-substituted cycloalkyl and polycycloalkyl alpha-substituted Trp-Phe- and phenethylamine derivatives | WARNER LAMBERT CO (US) | 2004-09-08 | — | — | EP | claimed |
| WO-2026085582-A1 | PROTEIN CAGES | THE UNIVERSITY OF SYDNEY (AU) | 2026-04-30 | — | — | WO | disclosed |
| EP-4627079-A2 | THERMOSTABLE BINDING SCAFFOLDS | Nectagen, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4618968-A1 | MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF | Technion Research & Development Foundation Limited (IL) | 2025-09-24 | — | — | EP | disclosed |
| CN-120202191-A | Inhibitors of prostate specific membrane antigen and uses thereof | 上海先通生物科技有限公司 | 2025-06-24 | — | — | CN | disclosed |
| EP-4551563-A2 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025091087-A1 | BISPECIFIC PROTEINS | MONASH UNIVERSITY (AU) | 2025-05-08 | — | — | WO | disclosed |
| CN-119816487-A | FC conjugates comprising CD73 inhibitors and uses thereof | 奇达拉治疗公司 | 2025-04-11 | — | — | CN | disclosed |
| WO-1994004494-A1 | TACHYKININ ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1994-03-03 | — | — | WO | disclosed |
| WO-1994003483-A1 | ENDOTHELIN RECEPTOR-BINDING COMPOUNDS | CHIRON CORPORATION (US) | 1994-02-17 | — | — | WO | disclosed |
| US-5278316-A | Indoles | WARNER-LAMBERT COMPANY (US) | 1994-01-11 | — | — | US | disclosed |
| US-5264419-A | N-substituted cycloalkyl and polycycloalkyl α-substituted TRP derivatives | WARNER-LAMBERT COMPANY (US) | 1993-11-23 | — | — | US | disclosed |
| EP-0479910-A1 | N-SUBSTITUTED CYCLOALKYL AND POLYCYCLOALKYL ALPHA-SUBSTITUTED Trp-Phe- AND PHENETHYLAMINE DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1992-04-15 | — | — | EP | disclosed |
| WO-1991000274-A1 | N-SUBSTITUTED CYCLOALKYL AND POLYCYCLOALKYL ALPHA-SUBSTITUTED TRP-PHE- AND PHENETHYLAMINE DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1991-01-10 | — | — | WO | disclosed |
| US-4757151-A | Pharmaceuticals | WARNER-LAMBERT COMPANY (US) | 1988-07-12 | — | — | US | disclosed |
| EP-0224151-A2 | 2-Substituted-[2-substituted-amino]-N-aralkyl-3-[indol-3-yl]propanamides | WARNER-LAMBERT COMPANY (US) | 1987-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215895-A1 | Therapeutic and carrier molecules | PHKG1, PHKG2, DGKB | MAPT 3161/4885MEN1 3261/4885KMT2A 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.